The Patent 1000 focuses exclusively on patent practice and has firmly established itself as the definitive 'go-to' resource for those seeking world-class legal patent expertise.
Silver - Firms: litigation
Recommended - Firms: transactions
Gold - Firms: prosecution
Carpmaels & Ransford was one of the first outfits to combine the services of patent attorneys and solicitors, a working model that continues to be successful and has been copied by many others in the market. Its EPO opposition practice is one of the largest in the whole of Europe, it steps in regularly to resolve court disputes, and it has a powerful IP transactional group too. In the words of interviewees: “They are very good, hands-on practitioners, who also excel at client management and often have creative suggestions for avoiding litigation. Of all the English firms we have worked with, they provide the most balanced and genuinely helpful advice. The patent attorneys are at the top of their game and provide useful litigation support.” The team on the litigation side is led by David Wilson and includes Ian Kirby, Camilla Balleny and Jennifer Antcliff. Wilson and Kirby have each been acting in multi-jurisdictional patent battles for over 25 years – Wilson is especially strong in disputes that arise in the context of licence agreements, while Kirby stands out as an advocate of alternative dispute resolution. Life sciences – and especially pharmaceutical and SPC cases – are the focus of both Balleny and Antcliff, with Balleny benefiting from a degree in genetics and time spent in-house and Antcliff holding a PhD in molecular biology. Handling pharmaceutical work on the prosecution side are the likes of James Warner, Edward Oates and Daniel Wise. Warner leads the pharmaceutical group and is well known for handling multi-opponent oppositions, including rare cases with more than 10 opponents; the same is true of Oates, who has dealt with proceedings with 14 and 15 opponents on behalf of some of the world’s largest pharmaceutical companies. Wise, on the other hand, counts vaccine technology and protein therapeutics among his specialisms and has a granular knowledge of SPCs. Heading up the biotechnology team is Mark Chapman, an expert patent drafter and defender whose technical strengths include antisense therapeutics and antibody therapeutics; his fellow biotechnology ace is Cameron Marshall, who works alongside blue-chip clients from the early stages, anticipating then batting away threats. Also on the life sciences side are Harvey Adams and Hugh Goodfellow – Adams has carved a niche defending patents for well-known drugs in abbreviated new drug application litigation, and also deftly handles freedom-to-operate issues, while Goodfellow acts as the firm’s managing partner and life sciences business lead, capably files and prosecutes SPCs, and is frequently seen before both the EPO and European Court of Justice. Captaining the engineering and technology side is Gary Small, who has historically been enlisted by the likes of Hewlett-Packard and Johnson & Johnson. His team includes Chris Tunstall and John Brunner, who have been jointly involved in a set of crucial EPO oppositions for the latter company in relation to laser eye surgery. Also in the engineering and technology teams is Paul Bettridge, who specialises in medical devices patents and works with patrons ranging from innovator SMEs to global healthcare companies. An integral member of the chemistry group, Susan Kirsch recently fought an appeal for Johnson & Johnson in relation to its Tylenol Rapid Release Gels. For transactional issues, the one to go to is Jake Marshall, who brings secondment experience at GSK and Gilead to his practice negotiating high-enddeals.
Carpmaels & Ransford LLP is a leader in the European IP market, having driven innovation in the industry for over 200 years. The firm advises clients on all aspects of intellectual property, including drafting, filing and prosecuting patent and trademark applications; drafting and negotiating licence agreements and other commercial IP agreements; advising on the transfer of property rights; assisting clients with patent restoration matters; and conducting enforcement and revocation litigation.
The firm has one of Europe’s largest IP teams serving blue-chip clients across the globe, including Johnson & Johnson, Bristol Myers Squibb, Novartis, Ionis Pharmaceuticals, Mars, Gilead, Raytheon, Regeneron, Takeda, Allergan and Xeros. The firm’s attorneys have considerable technical knowledge, bringing together experience from industry-leading companies, academic research at leading universities and extensive patent expertise in the areas of engineering and tech, chemistry and materials, pharmaceuticals, biotechnology, supplementary protection certificates and information and communication technologies and standards.
Through its fully integrated dispute resolution and transactions teams, the firm is able to provide a holistic service to clients which supports their IP needs from inception to commercialisation. The dispute resolution team, made up of experienced solicitors, barristers and patent attorney litigators, represents clients at all levels of the European Patent Office. The team is also adept at conducting enforcement litigation and revocation actions before the UK Intellectual Property Office and patent, copyright, trademark and other IP litigation in the English courts and the Court of Justice of the European Union, often advising in cases where parallel or related litigation is ongoing in courts across Europe or in the United States.
The transactions team is another key part of the firm’s integrated IP offering. As well as advising on the acquisition and licensing of IP rights and other IP-focused agreements (eg, development and collaboration agreements), the team manages multi-jurisdictional patent/trademark assignment recordal projects, provides specialist advice on the transfer of priority rights and assists clients with the restoration of registered IP rights around the world.
As a European IP firm with litigators and patent attorneys under one roof, Carpmaels & Ransford are looking forward to offering clients the chance to both obtain UPs using the existing EPO procedure and enforce their patents across Europe in the UPC.